Lisa Rydén
141 – 150 of 211
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2014
-
Mark
Invasive lobular carcinoma of the breast: long-term prognostic value of Ki67 and histological grade, alone and in combination with estrogen receptor.
(
- Contribution to journal › Article
-
Mark
High frequency of myeloid-derived suppressor cells in sepsis patients, with the granulocytic subtype dominating in Gram-positive cases
(
- Contribution to journal › Published meeting abstract
-
Mark
Abstract P2-10-28: The Prognostic Index, KiGE, Combining Proliferation, Histological Grade and Estrogen Receptor Status Challenges Gene Profiling – A Study in 1,854 Chemo-Naïve Women with N0/N1 Primary Breast Cancer.
(
- Contribution to journal › Published meeting abstract
- 2013
-
Mark
The combination of Ki67, histological grade and estrogen receptor status identifies a low-risk group among 1,854 chemo-naïve women with N0/N1 primary breast cancer.
(
- Contribution to journal › Article
-
Mark
St Gallen molecular subtypes in primary breast cancer and matched lymph node metastases - aspects on distribution and prognosis for patients with luminal A tumours: results from a prospective randomised trial
(
- Contribution to journal › Article
-
Mark
The prognostic significance of wnt-5a expression in primary breast cancer is extended to premenopausal women.
(
- Contribution to journal › Article
-
Mark
Biomarker expression and St Gallen molecular subtype classification in primary tumours, synchronous lymph node metastases and asynchronous relapses in primary breast cancer patients with 10 years' follow-up.
(
- Contribution to journal › Article
-
Mark
The role of AIB1 and PAX2 in primary breast cancer: validation of AIB1 as a negative prognostic factor.
(
- Contribution to journal › Article
-
Mark
Targeting HMG-CoA reductase with statins in a window-of-opportunity breast cancer trial.
(
- Contribution to journal › Article
-
Mark
Completion axillary dissection can safely be omitted in screen detected breast cancer patients with micrometastases. A decade's experience from a single institution.
(
- Contribution to journal › Article